Revolution Medicines $RVMD pancreatic cancer pill has officially been FDA approved as of 8/26
Cost? $39,800/month for patients suffering from late stage cancer
The stock is +167% YTD
Revolution Medicines ($RVMD) won FDA approval for Rasonque, a first-of-its-kind targeted pancreatic cancer drug.
In Phase 3, the treatment cut death risk by 60% and nearly doubled median overall survival versus chemotherapy.
Revolution CEO and Bloomberg Opinion contributor Steve Case says AI will disrupt a wide range of industries and business models, advising investors to seek assets that have better durability. Case points to real estate and hospitality as areas attracting investment
Revolution Medicines secured US regulatory approval for its pancreatic cancer drug daraxonrasib, the first medicine to target one of the key molecular causes of the disease